Literature DB >> 971704

Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy.

M Eichelbaum, L Bertilsson, L Lund, L Palmér, F Sjöqvist.   

Abstract

Carbamazepine and its epoxide in plasma were measured by liquid chromatography in 25 patients treated with a mean dose of carbamazepine of 12.5 +/- 3.3 mg/kg body weight. The mean concentrations of parent drug and metabolite were 5.4 +/- 2.5 mug/ml and 1.10 +/- 0.42 mug/ml, respectively. A singificant correlation was found between the plasma concentrations of the two compounds (r = 0.64; p less than 0.001), but marked interindividual variation existed in the ratio of carbamazepine to carbamazepine to epoxide. Based on simultaneous measurements in plasma and cerebrospinal fluid, the unbound fraction of carbamazepine in plasma was of the order of 20% as compared to 45% for the epoxide. Thirteen ambulant patients suffering from partial epilepsy with complex symptomatology, who were already being treated with phenytoin in optimal doses (plasma level 14-20 mug/ml) were also given carbamazepine. At plasma levels of the latter of about 5 mug/ml there was no further reduction in the frequency of partial or generalized epileptic seizures. In five patients the dose was increased to produce plasma concentrations of 7 - 8 mug/ml. There was still no improvement and side-effects were seen in three patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971704     DOI: 10.1007/BF00606558

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  TIC DOULOUREUX TREATED WITH NEW ANTICONVULSANT; EXPERIENCES WITH G 32883.

Authors:  S BLOM
Journal:  Arch Neurol       Date:  1963-09

2.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

3.  Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography.

Authors:  M Eichelbaum; L Bertilsson
Journal:  J Chromatogr       Date:  1975-01-14

4.  Mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine.

Authors:  A Frigerio; R Fanelli; P Biandrate; G Passerini; P L Morselli; S Garattini
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

5.  Carbamazepine plasma and tissue levels in the rat.

Authors:  P L Morselli; M Gerna; S Garattini
Journal:  Biochem Pharmacol       Date:  1971-08       Impact factor: 5.858

6.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

7.  Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures.

Authors:  L Lund
Journal:  Arch Neurol       Date:  1974-11

8.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

9.  Some causes of ineffectiveness of diphenylhydantoin.

Authors:  H Kutt; J Haynes; F McDowell
Journal:  Arch Neurol       Date:  1966-05

10.  Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy.

Authors:  S I Johannessen; R E Strandjord
Journal:  Epilepsia       Date:  1973-12       Impact factor: 5.864

View more
  11 in total

Review 1.  Therapeutic drug monitoring for tomorrow.

Authors:  Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

4.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Clinical pharmacokinetics in infants and children.

Authors:  A Rane; J T Wilson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

9.  Carbamazepine and its 10,11-epoxide in children and adults with epilepsy.

Authors:  S Pynnönen; M Sillanpää; H Frey; E Iisalo
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

10.  Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients.

Authors:  K Ghose; D E Fry; J A Christfides
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.